133 related articles for article (PubMed ID: 37219413)
1. Clinical Images: Degos-like lesions in association with NXP-2 dermatomyositis.
Alhassan E; Wu KK; Christianakis S; Kim G; Crew A
ACR Open Rheumatol; 2023 Sep; 5(9):435. PubMed ID: 37219413
[No Abstract] [Full Text] [Related]
2. Degos-Like Lesions In Association With Connective Tissue Diseases: A Report Of Three Cases And Literature Review.
Stavorn T; Chanprapaph K
Clin Cosmet Investig Dermatol; 2019; 12():815-822. PubMed ID: 31807047
[TBL] [Abstract][Full Text] [Related]
3. Degos-Like Cutaneous Findings in an Adult Woman With NXP-2-Associated Dermatomyositis.
Giacalone S; Moltrasio C; Nazzaro G
JAMA Dermatol; 2020 Feb; 156(2):218-220. PubMed ID: 31876929
[No Abstract] [Full Text] [Related]
4. Juvenile dermatomyositis resembling late-stage Degos disease with gastrointestinal perforations successfully treated with combination of cyclophosphamide and rituximab: case-based review.
Day W; Gabriel C; Kelly RE; Magro CM; Williams JV; Werner A; Gifford L; Lapsia SP; Aguiar CL
Rheumatol Int; 2020 Nov; 40(11):1883-1890. PubMed ID: 31900501
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.
Rogers A; Chung L; Li S; Casciola-Rosen L; Fiorentino DF
Arthritis Care Res (Hoboken); 2017 Dec; 69(12):1909-1914. PubMed ID: 28129490
[TBL] [Abstract][Full Text] [Related]
6. Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies.
Liu Y; Zheng Y; Gang Q; Xie Z; Jin Y; Zhang X; Deng X; Hao H; Gao F; Zhang Z; Xiong H; Zhang W; Wang Z; Yuan Y
Eur J Neurol; 2020 Mar; 27(3):514-521. PubMed ID: 31571350
[TBL] [Abstract][Full Text] [Related]
7. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
8. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.
Albayda J; Pinal-Fernandez I; Huang W; Parks C; Paik J; Casciola-Rosen L; Danoff SK; Johnson C; Christopher-Stine L; Mammen AL
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1771-1776. PubMed ID: 28085235
[TBL] [Abstract][Full Text] [Related]
9. A Case of Dermatomyositis Coexisting with Both Anti-Mi-2 and Anti-NXP-2 Antibodies.
Ito M; Moriya C; Matsuyama K; Shu E; Hamaguchi Y; Seishima M
Case Rep Dermatol; 2020; 12(2):92-97. PubMed ID: 32508616
[TBL] [Abstract][Full Text] [Related]
10. Is Degos' disease a clinical and histological end point rather than a specific disease?
High WA; Aranda J; Patel SB; Cockerell CJ; Costner MI
J Am Acad Dermatol; 2004 Jun; 50(6):895-9. PubMed ID: 15153891
[TBL] [Abstract][Full Text] [Related]
11. Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
Inoue M; Tanboon J; Hirakawa S; Komaki H; Fukushima T; Awano H; Tajima T; Yamazaki K; Hayashi R; Mori T; Shibuya K; Yamanoi T; Yoshimura H; Ogawa T; Katayama A; Sugai F; Nakayama Y; Yamaguchi S; Hayashi S; Noguchi S; Tachimori H; Okiyama N; Fujimoto M; Nishino I
JAMA Neurol; 2020 Jul; 77(7):872-877. PubMed ID: 32310254
[TBL] [Abstract][Full Text] [Related]
12. Degos disease with dermatomyositis-like phenomenon: a diagnostic dilemma and a therapeutic challenge.
Gupta S; Dogra S; Saikia UN; Yadav S; Kanwar AJ
J Cutan Med Surg; 2011; 15(3):162-6. PubMed ID: 21561585
[TBL] [Abstract][Full Text] [Related]
13. A rare case of NXP-2 positive dermatomyositis.
Khan N; Kazmi ZH; Alkhateb R
Arch Clin Cases; 2020; 7(4):68-71. PubMed ID: 34754931
[TBL] [Abstract][Full Text] [Related]
14. Degos-Like Lesions Associated with Systemic Lupus Erythematosus.
Jang MS; Park JB; Yang MH; Jang JY; Kim JH; Lee KH; Kim GT; Hwangbo H; Suh KS
Ann Dermatol; 2017 Apr; 29(2):215-218. PubMed ID: 28392651
[TBL] [Abstract][Full Text] [Related]
15. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
[TBL] [Abstract][Full Text] [Related]
16. Degos' disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per se.
Ball E; Newburger A; Ackerman AB
Am J Dermatopathol; 2003 Aug; 25(4):308-20. PubMed ID: 12876488
[TBL] [Abstract][Full Text] [Related]
17. NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation.
Butt Z; Patel L; Das MK; Mecoli CA; Ramji A
Case Rep Rheumatol; 2017; 2017():4817275. PubMed ID: 28695037
[TBL] [Abstract][Full Text] [Related]
18. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
Ishikawa A; Muro Y; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
[TBL] [Abstract][Full Text] [Related]
19. Degos-like lesions as a cutaneous manifestation of cytomegalovirus infection: A rare and serious complication in a patient with drug-induced hypersensitivity syndrome.
Chieosilapatham P; Prinyaroj N; Jamjanya S; Kiratikanon S; Thinrungroj N; Kaewpoowat Q; Kongkarnka S; Mahanupab P; Tovanabutra N; Chiewchanvit S; Chuamanochan M
J Dermatol; 2021 Apr; 48(4):533-536. PubMed ID: 33305840
[TBL] [Abstract][Full Text] [Related]
20. Lesions resembling malignant atrophic papulosis in a patient with dermatomyositis.
Tsao H; Busam K; Barnhill RL; Haynes HA
J Am Acad Dermatol; 1997 Feb; 36(2 Pt 2):317-9. PubMed ID: 9039209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
